Gastroesophageal Reflux Disease News and Research RSS Feed - Gastroesophageal Reflux Disease News and Research

Statins reduce patient's risk of developing Barrett's esophagus

Statins reduce patient's risk of developing Barrett's esophagus

Statins, a class of drugs commonly used to lower cholesterol levels, significantly reduce a patient's risk of developing Barrett's esophagus, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
LINX Reflux Management System safe for patients suffering from GERD, shows new data

LINX Reflux Management System safe for patients suffering from GERD, shows new data

Torax Medical today announced the release of new data from two leading U.S. medical centers that further establishes the LINX Reflux Management System as a safe and effective procedure for patients suffering from gastroesophageal reflux disease (GERD). [More]
FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Therapeutics, LLC, today announced that the Company has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex® Sprinkle™ (rabeprazole sodium), Delayed-Release Capsules, 5 mg and 10 mg, for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks. [More]
Effects of radiofrequency ablation and complete endoscopic resection are equal in dysplastic Barrett's esophagus

Effects of radiofrequency ablation and complete endoscopic resection are equal in dysplastic Barrett's esophagus

According to a new systematic review article, radiofrequency ablation and complete endoscopic resection are equally effective in the short-term treatment of dysplastic Barrett's esophagus, but adverse event rates are higher with complete endoscopic resection. [More]
Oral health: The gateway to your overall health

Oral health: The gateway to your overall health

If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health. [More]
Access provides update on new formulation of anti-inflammatory drug amlexanox

Access provides update on new formulation of anti-inflammatory drug amlexanox

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard™, for the treatment of inflammatory and ulcerative conditions of the esophagus. [More]
Study confirms safety of LINX Reflux Management System for GERD treatment

Study confirms safety of LINX Reflux Management System for GERD treatment

Millions of Americans suffer from Gastroesophageal Reflux Disease (GERD), a chronic, often progressive disease that can cause debilitating symptoms and lead to serious complications including pre-cancerous Barrett's esophagus and esophageal cancer. [More]
Infants who experience ALTEs have abnormal regulation of esophageal function

Infants who experience ALTEs have abnormal regulation of esophageal function

About 1 percent of all emergency room visits are prompted by near-death experiences in infants, such as extended periods without breathing or sudden changes in skin pallor or muscle tone. What causes these frightening experiences is often unknown, but the result can be long hospital stays and neurological impairment. [More]
Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015. [More]
Gastric bypass better than gastrectomy for GERD relief

Gastric bypass better than gastrectomy for GERD relief

Patients who are about to undergo bariatric surgery may be better off having a gastric bypass than a sleeve gastrectomy if they also suffer from heartburn, results of a large US analysis suggest. [More]
Doctors miss opportunities to diagnose COPD at an earlier stage in primary and secondary care

Doctors miss opportunities to diagnose COPD at an earlier stage in primary and secondary care

A retrospective study of almost 39,000 patients shows that opportunities to diagnose chronic obstructive pulmonary disease (COPD) at an earlier stage are frequently being missed in both primary and secondary care in the UK. The findings, published in The Lancet Respiratory Medicine, reveal missed opportunities to diagnose COPD occurred in up to 85% of people. [More]
Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Gastroesophageal Reflux Disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. [More]
Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal Pharmaceuticals LLC today announced the launch of its branded Esomeprazole Strontium 49.3 mg delayed-release capsules. Esomeprazole Strontium contains the same active moiety (esomeprazole) in a different salt form as found in the branded proton-pump inhibitor Nexium (esomeprazole magnesium) and is a new option for adult patients for the short term treatment of gastroesophageal reflux disease. [More]
Marker for inflammatory bowel disease linked to bipolar disorder

Marker for inflammatory bowel disease linked to bipolar disorder

Researchers have found evidence that the gastrointestinal tract plays a role in the inflammatory pathology of bipolar disorder, suggesting the need to consider dietary modification and anti-inflammatory treatment for some patients. [More]
Insomnia linked to increased GERD risk

Insomnia linked to increased GERD risk

Insomnia is associated with an increased risk for gastroesophageal reflux disease, findings from a cross-sectional study show. [More]
Reflux surgery challenged for smallest children

Reflux surgery challenged for smallest children

US physicians have raised concerns over the diagnosis and treatment of gastroesophageal reflux disease in small children, especially among infants for whom regurgitation is normal and likely to resolve with conservative treatment [More]
Mylan Pharmaceuticals launches Rabeprazole Sodium Delayed-release Tablets

Mylan Pharmaceuticals launches Rabeprazole Sodium Delayed-release Tablets

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Rabeprazole Sodium Delayed-release Tablets, 20 mg. [More]
First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

The U.S. Food and Drug Administration today approved the first generic versions of Aciphex (rabeprazole sodium) delayed-release tablets, used to treat gastroesophageal reflux disease in adults and adolescents (ages 12 and up). [More]
EGS announced that enrollment for RESPECT study has surpassed company's original target

EGS announced that enrollment for RESPECT study has surpassed company's original target

EndoGastric Solutions (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced today that enrollment for the RESPECT study (Randomized EsophyX vs. Sham/Placebo Controlled Trial) is complete and has surpassed the company's original target of 120 patients. [More]
Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening. [More]